KalVista Pharmaceuticals (KALV) Cash from Investing Activities Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -114.28% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 826.39% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -674.01% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -166.24% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -122.45% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -42.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -42.79% |
| Apr 30, 2025 | 97.36% |
| Oct 31, 2024 | 70.45% |
| Jul 31, 2024 | 89.48% |
| Apr 30, 2024 | -1,931.98% |
| Jan 31, 2024 | -166.27% |
| Oct 31, 2023 | 42.08% |
| Jul 31, 2023 | -34.72% |
| Apr 30, 2023 | -149.94% |
| Jan 31, 2023 | -119.51% |
| Oct 31, 2022 | 13.91% |
| Jul 31, 2022 | 101.90% |
| Apr 30, 2022 | 107.47% |
| Jan 31, 2022 | 85.77% |
| Oct 31, 2021 | 176.93% |
| Jul 31, 2021 | 169.93% |
| Apr 30, 2021 | -1,760.35% |
| Jan 31, 2021 | -28.92% |
| Oct 31, 2020 | 520.81% |
| Jul 31, 2020 | 460.33% |
| Apr 30, 2020 | 171.38% |
| Jan 31, 2020 | 117.90% |
| Oct 31, 2019 | -585.07% |
| Jul 31, 2019 | -170.80% |
| Apr 30, 2019 | -1,195.85% |
| Jan 31, 2019 | -29,893.96% |
| Oct 31, 2018 | -333.33% |
| Jul 31, 2018 | -413.64% |
| Apr 30, 2018 | -15,385.71% |
| Jan 31, 2018 | -100.53% |
| Oct 31, 2017 | -183.33% |
| Jul 31, 2017 | -155.81% |
| Mar 31, 2016 | -2.22% |
| Sep 30, 2015 | -200.00% |
| Jun 30, 2015 | -5.33% |
| Mar 31, 2015 | -17,900.00% |